NCT00489216View on ClinicalTrials.gov

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids

NATerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

October 31, 2008

Conditions
Graft Versus Host Disease
Interventions
BIOLOGICAL

efalizumab

"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"

Trial Locations (1)

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER